Exploring how vinpocetine may help improve cognitive issues from fetal alcohol exposure
Vinpocetine Mediation of Prior Fetal Alcohol Exposure
This study is looking at how a drug called vinpocetine might help improve thinking and learning skills in people who have cognitive challenges from fetal alcohol exposure, and it will first test the right amount of the drug in animals before moving on to trials with humans.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project ID | NIH-10954146 on NIH RePORTER |
What this research studies
This research investigates the potential of vinpocetine, a drug that may enhance neuronal plasticity, to treat cognitive impairments caused by fetal alcohol exposure. The study will first establish the effective dose of vinpocetine in animal models of Fetal Alcohol Spectrum Disorders (FASD) to determine the appropriate plasma concentrations needed for human trials. By understanding how different doses affect cognitive function, the research aims to pave the way for future clinical trials that could provide new treatment options for affected individuals.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with Fetal Alcohol Spectrum Disorders (FASD) or those who have experienced fetal alcohol exposure.
Not a fit: Patients without a history of fetal alcohol exposure or those not diagnosed with FASD may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for individuals with cognitive impairments due to fetal alcohol exposure.
How similar studies have performed: Previous studies have shown promising results with vinpocetine in animal models, suggesting potential for success in human applications.
Where this research is happening
Stanford, United States
- Stanford University — Stanford, United States (Active)
Researchers
- Principal investigator: Meador, Kimford J — Stanford University
- Study coordinator: Meador, Kimford J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.